John J. Crowley

John J. Crowley's AcademicInfluence.com Rankings

John J. Crowley

Philosophy

#5117

World Rank

#7843

Historical Rank

Logic

#2447

World Rank

#3440

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John J. Crowley's Degrees

Doctorate Medicine University of California, San Francisco

Why Is John J. Crowley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John J. Crowley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours (2007) (3431)
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. (1999) (2644)
The influence of finasteride on the development of prostate cancer. (2003) (2636)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. (2004) (2473)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
International staging system for multiple myeloma. (2005) (1929)
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. (2001) (1137)
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2011) (999)
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2007) (950)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008) (942)
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. (2001) (881)
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. (1995) (860)
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women (1988) (842)
A Confidence Interval for the Median Survival Time (1982) (750)
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. (1991) (742)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. (2017) (728)
A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship (1974) (720)
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. (2005) (671)
The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours (2007) (592)
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. (1998) (568)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. (2008) (544)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer (2015) (480)
Covariance Analysis of Heart Transplant Survival Data (1977) (473)
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. (2009) (458)
The revised TNM staging system for lung cancer. (2009) (455)
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. (1993) (455)
The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2009) (440)
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. (2009) (436)
Relative risk trees for censored survival data. (1992) (413)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer (2007) (411)
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. (1990) (386)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer (2007) (366)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer (2007) (361)
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2005) (352)
International prognostic scoring system for Waldenstrom macroglobulinemia. (2009) (332)
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. (2002) (330)
The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer (2009) (327)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2007) (325)
Survival Trees by Goodness of Split (1993) (325)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer (2015) (323)
The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition (2008) (315)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors (2014) (300)
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer (2014) (273)
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2008) (262)
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. (2000) (248)
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. (2002) (231)
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer (2017) (203)
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. (2010) (197)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. (1987) (196)
Patient income level and cancer clinical trial participation. (2013) (193)
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. (1993) (191)
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADViSE) (2017) (189)
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). (2010) (188)
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. (2009) (185)
Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy (2007) (183)
The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer (2016) (180)
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. (2008) (179)
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. (1995) (174)
Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma (2006) (174)
Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. (1990) (172)
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. (1984) (169)
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. (1993) (167)
Cure Models as a Useful Statistical Tool for Analyzing Survival (2012) (167)
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer (2006) (159)
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. (1993) (156)
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. (2005) (153)
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. (2001) (153)
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study (1995) (153)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Design of the Prostate Cancer Prevention Trial (PCPT). (1995) (150)
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. (2006) (149)
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. (2010) (149)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee (2010) (145)
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma (2008) (142)
[The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer]. (2010) (134)
A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study (2005) (130)
Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. (2004) (130)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. (2014) (127)
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). (2001) (127)
Randomized Phase II Designs (2009) (126)
Nonparametric Estimation of a Bivariate Survival Function in the Presence of Censoring (1986) (125)
Handbook of statistics in clinical oncology (2012) (122)
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. (2004) (121)
Solitary Brain Metastasis: Results of an RTOG/SWOG Protocol Evaluation Surgery + RT versus RT Alone (1990) (120)
Tests for differences in tumor incidence based on animal carcinogenesis experiments (1984) (120)
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. (2005) (120)
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience (2003) (112)
Analyzing survival data from clinical trials and observational studies (1996) (109)
Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. (1991) (109)
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. (2006) (109)
The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project (2009) (108)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. (2000) (106)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. (2004) (102)
Clinical Trials in Oncology (1997) (101)
Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. (1983) (101)
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. (2015) (100)
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. (1991) (97)
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. (2008) (95)
Randomized Phase III Clinical Trial Designs for Targeted Agents (2008) (95)
Chemoprevention of prostate cancer: The prostate cancer prevention trial (1997) (92)
Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232. (2007) (88)
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants (1994) (88)
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. (2013) (88)
A Diagnostic for Cox Regression and General Conditional Likelihoods (1985) (87)
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. (2013) (86)
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007 (2008) (84)
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. (2016) (81)
A general class of nonparametric tests for survival analysis. (1989) (81)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. (1995) (80)
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2004) (80)
Statistical analysis of survival data. (1984) (79)
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. (2002) (78)
Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. (1994) (77)
Nonparametric Inference for a Class of Semi-Markov Processes with Censored Observations (1984) (75)
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033 (2017) (74)
The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies (2013) (72)
A k-Sample Median Test for Censored Data (1982) (69)
Correction: A Large Sample Study of Generalized Maximum Likelihood Estimators from Incomplete Data via Self-Consistency (1985) (67)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors (2014) (67)
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. (2010) (65)
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). (2003) (64)
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. (2005) (63)
Local full likelihood estimation for the proportional hazards model. (1991) (63)
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. (1998) (61)
The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: the new era of data-driven revisions. (2010) (60)
Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) (2006) (60)
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. (1990) (60)
Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. (1984) (57)
Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer. (1982) (55)
Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors (2013) (55)
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) (2014) (54)
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. (1998) (53)
Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial (2002) (53)
Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to Therapy (2004) (53)
CORRELATION OF SERUM CYCLOSPORINE CONCENTRATION WITH RENAL DYSFUNCTION IN MARROW TRANSPLANT RECIPIENTS (1985) (52)
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. (2009) (52)
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. (2004) (51)
Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 (2007) (50)
Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. (2010) (50)
A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. (2012) (50)
Selection designs for pilot studies based on survival. (1993) (49)
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120) (2015) (47)
S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial (2007) (47)
Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 (2012) (46)
S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) (2008) (46)
A Large Sample Study of Generalized Maximum Likelihood Estimators from Incomplete Data Via Self-Consistency (1985) (45)
A note on nonparametric estimators of the bivariate survival function under univariate censoring (1998) (44)
A review of tree-based prognostic models. (1995) (44)
Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. (1994) (44)
Graphical Methods for Censored Data (1991) (43)
Interim futility analysis with intermediate endpoints (2008) (43)
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. (2006) (42)
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 (2008) (41)
Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base (1993) (41)
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. (1999) (41)
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. (2010) (41)
Whole brain irradiation and intrathecal Methotrexate in the treatment of solid tumor leptomeningeal metastases — A Southwest Oncology Group study (1988) (41)
The prostate cancer prevention trial: design, biases and interpretation of study results. (2006) (39)
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. (2015) (38)
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. (2018) (37)
A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. (2009) (37)
Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004) (2004) (37)
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma (2012) (36)
Chest irradiation (RT) vs. chest RT + chemotherapy ± prophylactic brain RT in localized non small cell lung cancer: A southwest oncology group randomized study (1990) (36)
Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents (2010) (35)
A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results (2008) (35)
Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru (2017) (32)
Practice effects in a longitudinal, multi-center Alzheimer’s disease prevention clinical trial (2012) (32)
Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer? (2010) (31)
Testing Against Ordered Alternatives for Censored Survival Data (1993) (31)
Some test statistics for use in multistate survival analysis (1983) (31)
Partitioning and peeling for constructing prognostic groups (2002) (30)
Freund's bivariate exponential distribution and censoring (1982) (30)
Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. (2006) (30)
Implementation of the Prostate Cancer Prevention Trial (PCPT). (2004) (30)
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. (2011) (30)
Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. (1990) (30)
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. (2006) (29)
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma (2013) (29)
Some Exploratory Tools for Survival Analysis (1997) (29)
Comparison of etoposide and cisplatin with bis‐chloro‐ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study (1990) (29)
Multiple Histology Phase II Trials (2009) (27)
A Reanalysis of the Stanford Heart Transplant Data: Comment (1983) (27)
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study (2019) (26)
Semiparametric Regression Functionals (1995) (26)
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). (2009) (26)
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. (2001) (26)
Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339). (2006) (25)
Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027) (2006) (25)
Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). (2004) (25)
Nonparametric tests of the Markov model for survival data (1992) (25)
Small randomized trials. (2007) (24)
Concurrent chemotherapy and radiotherapy for limited small-cell carcinoma of the lung: a Southwest Oncology Group Study. (1986) (24)
Estimated impact of the Prostate Cancer Prevention Trial on population mortality (2005) (23)
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. (1991) (22)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials (2004) (21)
Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia. (2011) (21)
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma (2016) (21)
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma (2017) (21)
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study (1997) (21)
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. (2001) (20)
Step‐function covariate effects in the proportional‐hazards model (1995) (19)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (19)
Evaluation of Multiple Models to Distinguish Closely Related Forms of Disease Using DNA Microarray Data: an Application to Multiple Myeloma (2004) (18)
Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. (1991) (18)
Moving a randomized clinical trial into an observational cohort (2013) (18)
Adaptive Risk Group Refinement (2005) (18)
Estimation of the ratio of hazard functions (1982) (17)
Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: A SWOG phase II trial (S0027) (2004) (17)
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents (2013) (17)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. (2004) (16)
Exploratory methods in survival analysis (1995) (16)
Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience. (1994) (16)
Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (16)
Asymptotic Normality of a New Nonparametric Statistic for Use in Organ Transplant Studies (1974) (16)
Challenges in clinical studies with multiple imaging probes. (2007) (15)
A randomized controlled trial of vitamin E and selenium on rate of decline in lung function (2015) (15)
O-89 S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial (2003) (15)
The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study (2002) (15)
Clinical Trials in Oncology, Second Edition (2002) (14)
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. (2001) (14)
Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. (1993) (13)
The Automatic Clinical Trial: Leveraging the Electronic Medical Record in Multisite Cancer Clinical Trials (2012) (12)
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study. (1986) (12)
The case against independent monitoring committees. (1994) (12)
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study (2007) (12)
Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group Study. (1987) (12)
Age-Expanded Normative Data for the Ruff 2&7 Selective Attention Test: Evaluating Cognition in Older Males (2012) (12)
Teniposide (VM‐26) as a single drug treatment for patients with extensive small cell lung carcinoma (1997) (11)
Remarks on the conservatism of sigma(0 -- E)2/E in survival data. (1975) (11)
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia : results of United States intergroup trial ( Southwest Oncology Group S 9003 ) (2001) (11)
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. (2014) (11)
Data monitoring committees for Southwest Oncology Group clinical trials. (1993) (11)
Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer. (1999) (10)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (10)
Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229). (1998) (10)
Biomarker-based methods for determining noncompliance in a prevention trial. (2002) (10)
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. (2004) (10)
Handbook of Statistics in Clinical Oncology, Second Edition (2005) (10)
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341) (2007) (10)
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. (2003) (10)
Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2011) (10)
A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study (2004) (9)
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma (2014) (9)
Phase II study of Fludarabine Phosphate in multiple myeloma (1990) (9)
Interpretation of survival data in clinical trials. (1991) (8)
Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design (2017) (8)
Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy (2008) (8)
396: Remarks on the Conservatism of Σ(0 - E) 2 /E in Survival Data (1975) (8)
Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics (2007) (8)
Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies (1993) (8)
A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The preadvise trial (2013) (8)
Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics. (2006) (8)
Oncology clinical trials (2013) (7)
Clinical Trials in Oncology, Third Edition (2012) (7)
On robust estimation of location for arbitrarily right-censored data (1986) (7)
High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. (2006) (7)
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy. (2020) (7)
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 (2007) (7)
Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design. (2006) (7)
Data Management and Quality Control (1997) (7)
Vindesine. A phase II trial in advanced breast cancer patients. (1981) (7)
Using the bootstrap for estimation in group sequential designs: an application to a clinical trial for nasopharyngeal cancer. (1999) (7)
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma (2016) (6)
Estimation of Cumulative Incidence in the Presence of Competing Risks (2005) (6)
Clinical trial designs for multiple myeloma. (2007) (6)
Multi‐subgroup gene screening using semi‐parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma (2018) (6)
An implicitly defined parametric model for censored survival data and covariates. (1995) (6)
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120) (2016) (5)
Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126 (2008) (5)
Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease (2005) (5)
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group (1996) (5)
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. (1997) (5)
Use of Covariates in Randomization and Analysis of Clinical Trials (2012) (5)
9404 ORAL Long-term Survival on S0033 – a Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours (GISTs) (2011) (5)
Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 (2008) (5)
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. (2005) (4)
Survival Analysis with Gene Expression Arrays (2003) (4)
Evaluation of fludarabine phosphate in small cell carcinoma (1988) (4)
Tree‐Structured Statistical Methods (2014) (4)
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung (1992) (4)
Interdisciplinary Statistics: Clinical Trials in Oncology, Second Edition (2003) (4)
International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia (2017) (3)
Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials. (2009) (3)
Southwest Oncology Group: two decades of experience in non-small cell lung cancer. (2005) (3)
Mental Component Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males (2020) (3)
Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718 (2007) (3)
We probably have the answer: now what is the question? (2009) (3)
The Design of Clinical Trials (1997) (3)
Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study (1993) (3)
Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial (2016) (3)
Frontiers of Biostatistical Methods and Applications in Clinical Oncology (2017) (3)
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC): Review of the Southwest Oncology Group (SWOG) database (2000) (3)
Interim Analysis and Data Monitoring Committees (1997) (3)
DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies (2011) (3)
Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914 (2006) (3)
The Probability of Being in Response Function and Its Applications (2017) (3)
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors (1991) (3)
Report of the Ad Hoc Committee on Design of an Experiment on Double-Blind Refereeing (1993) (3)
E05-02: IASLC Staging Project: T-desriptors (2007) (3)
Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma. (2016) (2)
Phase II trial of 6-thioguanine in metastatic breast cancer. (1980) (2)
O-124 S9900: Preliminary “surgical” results of a phase III trial of surgeryalone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC) (2005) (2)
Constructing Prognostic Groups by Tree-Based Partitioning and Peeling Methods (2005) (2)
Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study. (1991) (2)
Prognostic Groups by Tree-Based Partitioning and Data Refinement Methods (2012) (2)
Phase II evaluation of bisantrene in refractory multiple myeloma (1991) (2)
Survival analysis : proceedings of the special topics meeting (1982) (2)
Creation of a semiannual report for a multicentre co-operative clinical trials group. (1992) (2)
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study. (1992) (2)
Phase II Trials Using Time-to-Event Endpoints (2005) (2)
Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study (1990) (2)
A pilot study of mitomycin-C and tamoxifen (MT) versus dibromodulcitol, adriamycin, and tamoxifen (DAT). (1982) (2)
Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia (2020) (2)
P-305 Mutant DNA in Southwest Oncology Group (SWOG) S0003 non-small cell lung cancer (NSCLC) patient plasma: Potential for monitoring response to therapy (2003) (2)
Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC) (2000) (2)
Clinical studies of a fast homoarginine-sensitive alkaline phosphatase in patients with cancer. (1981) (2)
Tree-Structured Statistical Methods (2005) (2)
Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM). (2011) (1)
D1-04: Cisplatin (Cis) + etoposide (VP16) vs. cis + irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): Updated pharmacogenomic (SWOG 0124) and comparative toxicity analysis (JCOG 9511 & SWOG 0124) (2007) (1)
Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP). (2009) (1)
Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. (1993) (1)
Accrual patterns of the Southwest Oncology Group (SWOG) by sex, race/ethnicity, and age: Updated and expanded analyses. (2004) (1)
A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma (2004) (1)
Sufficient conditions for treatment responders to have longer survival than non-responders (1993) (1)
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). (2012) (1)
Extramedullary disease (EMD): A common terminal pathway in multiple myeloma (MM) progression. (2011) (1)
Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (1)
Evaluation of data collection using internet-based electronic case report forms (eCRFs) for a non-small-cell lung cancer (NSCLC) clinical trial (2005) (1)
[Evaluating Therapeutic Interventions: Some Issues and Experiences]: Comment (1992) (1)
IASLC Staging Project: T-desriptors: E05-02 (2007) (1)
A graphical approach to the analysis of censored data (2005) (1)
Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura. (2012) (1)
19 Utility of the enrollment period in the Prostate Cancer Prevention Trial (PCPT) (1997) (1)
Concommittant chemo radiotherapy in limited smallcell carcinoma of lung: Improved response and median survival. A southwest oncology group study (1987) (1)
Gene expression profiling (GEP) of cd 138-purified plasma cells (pc) in previously treated multiple myeloma (PTMM): Validating prognostic models developed in newly diagnosed MM (NDMM). (2009) (1)
E- 19. Lung Cancer Clinical Trials: Principles and Pitfalls (2003) (1)
Final results of a phase II trial of bexarotene capsules as 3rd or subsequent line therapy in patients with advanced non-small cell lung cancer (NSCLC). (2006) (1)
Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer (1993) (1)
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. (1981) (1)
An assay of angiogenic protein expression in human umbilical vein endothelial cells (HUVECs) (2005) (1)
Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study (2004) (1)
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. (1991) (1)
Phase I Trials (2012) (0)
SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC) (2008) (0)
Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003. (2004) (0)
Reply to J.C. Regelink et al (2010) (0)
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma (1991) (0)
Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity (2012) (0)
Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study (1993) (0)
Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics. (2006) (0)
Clinical staging of small cell lung cancer: report of the International Association for the Study of Lung Cancer Staging Initiative, Small Cell Lung Cancer Subcommittee: E05-06 (2007) (0)
WS-01: Clinical trials and biostatistics workshop: introduction and overview (2007) (0)
Effect Of Vitamin E And Selenium On Incidence Of Physician-Diagnosed COPD: The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2010) (0)
Phase III Oncology Clinical Trials (2018) (0)
(Southwest Oncology Group S9003) Waldenström macroglobulinemia: results of United States intergroup trial Prognostic factors and response to fludarabine therapy in patients with (2013) (0)
Abstract SY26-02: SWOG S0701 phase III randomized trial of three antibiotic regimens to eradicate helicobacter pylori: efficacy and failure at one year (2012) (0)
Phase III Trials (2012) (0)
D3-02: Updated Paclitaxel-Carboplatin Pharmacogenomic (PG) Analysis of Japan-SWOG Common Arm Study in Advanced Non-Small Cell Lung Cancer (NSCLC) (2007) (0)
Y1-05: How to get a grant (2007) (0)
DesignofaPhaseIIIClinicalTrialwithProspectiveBiomarker Validation: SWOG S0819 (2012) (0)
P-306 Molecular abnormalities in anti-microtubule and DNA damage response pathways in non-small cell lung carcinomas (NSCLC): Southwest Oncology Group (SWOG) 9509 trial (2003) (0)
Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003. (2006) (0)
On the ratio of hazard functions in the presence of a nuisance covariate (1990) (0)
Designs Using Time-to-Event Endpoints/Single-Arm versus Randomized Phase II Designs (2012) (0)
Clinical Trial Designs for the 21st Century: What are adaptive designs and what role do they play in SWOG's future? (2010) (0)
Randomized design and analysis of randomized clinical trials (1986) (0)
Efficacy for Targeted Agents Seamless Phase I-II Trial Design for Assessing Toxicity and (2011) (0)
Reply to J. Mehta (2011) (0)
Exploratory and High-Dimensional Data Analyses (2012) (0)
Reporting of Results (1997) (0)
MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3. (2009) (0)
Randomized Phase IIDesigns (2009) (0)
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study. (1991) (0)
Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity (2014) (0)
ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials (2020) (0)
Interdisciplinary statistics clinical trials in oncology (2012) (0)
Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total therapies 2 and 3. (2009) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
Discussion of Paper by P.K. Andersen, Ø. Borgan, R. Gill and N. Keiding@@@Discussion of Paper by P.K. Andersen, O. Borgan, R. Gill and N. Keiding (1982) (0)
Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival. (2009) (0)
Comment on: the prostate cancer prevention trial : Design, biases and interpretation of study results. Author's reply (2006) (0)
Volume Contents (2004) (0)
Multi-arm Trials (1997) (0)
Phase III Trials for Targeted Agents (2012) (0)
PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
An open letter to the American Society of Clinical Oncology. (1998) (0)
Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for which Time to Disease Progression is the Primary Endpoi t Running title : Phase II Trial Design for Time to Progression (2000) (0)
Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (0)
E17. New statistical methods in translational research and targeted therapy trials (2005) (0)
Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer (2010) (0)
Comprar Clinical Trials in Oncology 3ed | John Crowley | 9781439814482 | CrcPress (2012) (0)
Statistics in Clinical Cancer Research CureModels asaUseful Statistical Tool forAnalyzingSurvival (2012) (0)
WILLIAM F. ROSENBERGER, JOHN M. LACHIN. Randomization in Clinical Trials: Theory and Practice, 2nd edition. Hoboken: John Wiley & Sons (2017) (0)
Phase II Trials (2012) (0)
macroglobulinemia International prognostic scoring system for Waldenstrom's (2009) (0)
Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study. (1993) (0)
Statistical Issues in the Design and Analysis of Clinical Studies in Myeloma (2009) (0)
Can we cure Multiple Myeloma by 2020? Yes (2015) (0)
Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy. (2005) (0)
MS 17.06 Avoiding Phase II-III Attrition: Enhanced Biomarkers, Better Drugs or Improved Trial Design? (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John J. Crowley?

John J. Crowley is affiliated with the following schools:

University of Arkansas for Medical Sciences
University of Mississippi
Louisiana State University
Wayne State University
University of California, Davis
Stanford University
University of Colorado
University of Toronto
Columbia University
University of Salamanca
Kyoto University